Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,348 INR
Change Today +61.00 / 1.86%
Volume 43.2K
As of 7:05 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline pharmaceutic (GLXO) Snapshot

Open
3,255
Previous Close
3,287
Day High
3,400
Day Low
3,255
52 Week High
01/27/15 - 3,550
52 Week Low
08/12/14 - 2,400
Market Cap
283.6B
Average Volume 10 Days
14.0K
EPS TTM
56.87
Shares Outstanding
84.7M
EX-Date
07/23/15
P/E TM
58.9x
Dividend
62.50
Dividend Yield
--
Current Stock Chart for GLAXOSMITHKLINE PHARMACEUTIC (GLXO)

Related News

No related news articles were found.

glaxosmithkline pharmaceutic (GLXO) Related Businessweek News

No Related Businessweek News Found

glaxosmithkline pharmaceutic (GLXO) Details

GlaxoSmithKline Pharmaceuticals Limited operates as research-based healthcare and pharmaceutical company worldwide. It manufactures, distributes, and trades prescription medicines for a range of therapeutic areas, including analgesic, anti-infective, anti-inflammatory, anti-parasitic, cardiovascular, dermatology, diabetes, endocrine, gastrointestinal, gynaecology, immunosupressants, nutritional, respiratory, CNS, and oncology diseases. The company also offers vaccines for the prevention of various diseases comprising hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia, and others. GlaxoSmithKline Pharmaceuticals Limited was founded in 1924 and is based in Mumbai, India.

Founded in 1924

glaxosmithkline pharmaceutic (GLXO) Top Compensated Officers

Managing Director, Executive Director and Mem...
Total Annual Compensation: 26.1M
Executive Director of Technical and Executive...
Total Annual Compensation: 7.0M
Executive Director of Human Resources and Exe...
Total Annual Compensation: 7.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline pharmaceutic (GLXO) Key Developments

GlaxoSmithKline Pharmaceuticals Announces Executive Changes, Effective August 01, 2015

GlaxoSmithKline Pharmaceuticals has reported the Board of Directors of the Company at its meeting held on June 22, 2015 appointed Annaswamy Vaidheesh, as Vice President, South Asia & Managing Director of the company effective August 03, 2015. He succeeds, Dr. Hasit Joshipura, current Managing Director who will vacate office effective August 01, 2015.

GlaxoSmithkline Pharmaceuticals Limited, Board Meeting, Jun 22, 2015

GlaxoSmithkline Pharmaceuticals Limited, Board Meeting, Jun 22, 2015. Agenda: To appoint Mr. Annaswamy Vaidheesh, as Vice President, South Asia & Managing Director of the company effective August 03, 2015 succeeds, Dr. Hasit Joshipura, current Managing Director who will vacate office effective August 01, 2015.

Competition Commission of India Imposes INR 640 Million Fine on Glaxosmithkline and Sanofi

The Competition Commission of India (CCI) has slapped a INR 640 million penalty on GlaxoSmithKline Pharmaceuticals and Sanofi for collusive bidding in the government tender for supply of meningitis vaccine for Haj pilgrims. The matter relates to information filed by Bio-Med Private Limited against the Union of India through Deputy Assistant Director General (Stores), Medical Store Depot (DADG) in the ministry of health and family welfare. Bio-Med alleged that GlaxoSmithKline Pharmaceutical Limited and Sanofi collided in the tendering for polysaccharide Quadrivalent Meningococcal Meningitis vaccines in contravention of the provisions of the anti-trust Act. CCI imposed a fine of INR 604.5 million on GlaxoSmithKline and INR 30.4 million on Sanofi. The penalties amount to 3% of their three-year average turnover. In this case, turnovers of the two companies for the financial years 2008, 2009 and 2010 have been taken into account. The Commission, however, noted that the government was not an enterprise under the Act and therefore, did not direct any investigation against it.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLXO:IN 3,348.10 INR +61.00

GLXO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GLXO.
View Industry Companies
 

Industry Analysis

GLXO

Industry Average

Valuation GLXO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PHARMACEUTIC, please visit www.gsk-india.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.